-
August 06,2024Milestone: EnitiateBio QY201 Tablets for Moderate to Severe Atopic Dermatitis Phase II clinical trial reaches primary endpointEnitiate Bio has achieved its primary endpoint in the Phase II clinical trial of QY201 Tablets, a Class 1 innovative drug independently developed by Enitiate Bio, for the treatment of moderate-to-severe atopic dermatitis, with statistically significant and clinically meaningful results, as well as favorable safety and tolerability.More -
August 29,2023E-nitiate Biopharmaceuticals' QY201 Tablets Achieved the Milestone of the First-Patient-In of Phase II Clinical Study on Efficacy and Safety in Patients with Moderate-to-Severe Atopic DermatitisQY201, an orally administered tablet, is a new generation JAK1/TYK2 inhibitor independently developed by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (hereinafter referred to as "EnitiateBio") has entered the phase II clinical trial.More -
August 18,2023Setting Sail for the Sea – FDA Filing the IND Approval for QY201 of EnitiateBioOn July 26, 2023, Beijing time, E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (hereinafter referred to as "EnitiateBio" or "Qiyuan") received the IND approval for QY201 from the FDA. This is the first clinical approval obtained by EnitiateBio from the FDA and the first U.S. IND application that was fulfilled by EnitiateBio on its own, marking the official launch of the overseas expansion plan of EnitiateBio QY201.More -
June 07,2023Good News！ E-nitiate Biopharmaceuticals Biologics was elected as the vice chairman of Pharma-Derma-Alliance, CEO Kevin Ding was elected Vice Chairman of Pharma-Derma-AllianceOn June 2, the inaugural meeting of thePharma-Derma-Alliance (PhDA) and the first Dermatology New Drug Clinical Research Summit Forum were held in Beijing; the alliance aims to strengthen synergistic innovation and scientific innovation in dermatology clinical research, new drug development and results transformation, and promote the linkage of "government, industry, academia, research and medicine", so as to promote the high-quality development and globalization of the dermatology innovative drug industry. The Alliance aims to promote the development and globalization of the dermatology innovative drug industry to benefit dermatology patients in China and around the world.More -
May 12,2023Zhejiang Jingwei'sOn October 30, 2022, the company's Chairman and Chief Scientist, Dr. Wang Shen, Chief Executive Officer, Mr.Kevin Ding, and Chief Medical Officer, Mr. Jun Shi , were interviewed by Zhejiang Jing TV's "Creators World" to exchange and share their experiences around the company's development, the prospect of the pharmaceutical industry, and innovation and entrepreneurship.More
